Introduction
Complement cascade plasma proteins, the key components of the innate immune system, play a complex role in systemic lupus erythematosus (SLE) etiopathogenesis. It has been known for decades that activation of the complement system is necessary for subsequent tissue inflammation and damage after immune complex deposition. However, and paradoxically, deficiencies of different components of the complement classical pathway (for example, C1, C2 and C4) have also been associated with the development of SLE. [1] [2] [3] Complement proteins not only play important roles in the host resistance to bacterial infection, but also in the clearance of immune complexes and therefore, in the prevention of autoimmunity. In addition, complements play important roles in lymph node organization, B-cell maturation, differentiation and tolerance, as well as in immunoglobulin G isotype switching. 4, 5 C2, C4A, C4B and factor B are complement components with genetic locations within the major histocompatibility complex (MHC) class III region. Different alleles of these three components are linked to particular HLA (human leukocyte antigen) haplotypes and are inherited as extended MHC haplotypes or complotypes. Considerable differences in complotype frequencies have been observed among various SLE racial groups. [6] [7] [8] C1q is the first component of the classical pathway of complement activation and, together with the enzymatically active components C1r and C1s, forms the C1 complex. Binding of C1 to immunoglobulins in the form of immune complexes leads to the activation of proteases C1r and C1s and to a further activation of the classical pathway of complement. Complete C1q deficiency, although rare, is highly predictive of the risk for lupus (490%) and is associated with severe disease and glomerulonephritis. Approximately 20 families with C1 (C1q, C1r, C1s) deficiencies have been described in the literature and heterozygous deficiencies are difficult to identify. 9, 10 C1q is composed of three different species of chains, namely A, B and C. The genes for the A, B and C chains of C1q are arranged tandemly from 5 0 to 3 0 in the order A-C-B on a 24-kb stretch of DNA and closely linked together on chromosome 1p36. 12 C1q deficiency is caused either by a failure to synthesize C1q or by synthesis of low molecular weight C1q. 10 Different coding mutations have been identified that lead to a premature termination codon at different amino acid residues. [9] [10] In addition to coding mutations in patients with complete deficiency of C1q, which are very rare, a common silent single nucleotide polymorphism (SNP) (GGG-GGA) (rs172378) of the C1qA gene has been found to be associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus (SCLE). 11 The cause of such reduced levels of C1q is not known.
In this report, we describe the results of a fine mapping study, in which we evaluated 17 SNPs spanning C1Q genes on chromosome 1 in a large collection of 2214 African-American and Hispanic lupus cases and controls. This study is the largest published study of these genes in SLE and the first to investigate associations in African Americans and Hispanics.
Results

Lack of association of SLE with C1q
To determine whether C1q associates with SLE, we genotyped 16 SNPs in C1q that span C1A, C1C and C1B genes in our patients. SNPs were selected from the tag SNPs genotyped by the International HapMap Project to capture common variations in this region (r 2 40.8) plus additional rare coding SNPs. After removing monomorphic SNPs and those that were out of the HardyWeinberg equilibrium, 11 and 12 SNPs were subsequently used for analyses in African Americans and Hispanics, respectively. Furthermore, one additional SNP (rs172378) that had been genotyped earlier in part of these samples was merged into this dataset. This SNP, also known as C1qA-Gly70, has been associated with SCLE as mentioned earlier. 11 We did not observe a significant association with any of the selected SNPs in our populations using the presence of SLE as a phenotype (data not shown).
Subset analyses
We then evaluated these SNPs and cases selected for the presence of each of the 11 ACR (American College of Rheumatology) criteria, the presence of autoantibodies (anti-Ro, anti-La, anti-RNP (anti-ribonucleoprotein antibody), anti-dsDNA, anti-Sm), gender and age at onset for association with SLE. In addition, to verify that we had sufficient power for detecting a moderate effect, given the reduced sample sizes found in the subset analyses, we calculated the power for each subgroup presented below (see Materials and methods section). The power for each of the subset samples, assuming a type I error of 0.05 reported in the Results section are as follows: 293 cases/770 controls ¼ 0.95 (Table 1) , 125 cases/770 controls ¼ 0.66 (Table 2a) , 50 cases/209 controls ¼ 0.32 (Table 2b) , 128 cases/770 controls ¼ 0.67 (Table 3) , 141 cases/128 controls ¼ 0.71 (Table 4a ) and 249 cases/293 controls ¼ 0.92 (Table 4b) .
Apart from photosensitivity in African Americans that showed suggestive associations in multiple SNPs (0.05oPo0.005), there was no significant association in any of the selected SNPs with the ACR criteria. As photosensitivity tends to be negatively correlated with anti-dsDNA antibodies and therefore, a milder spectrum of disease, according to our data and other reports, 13 A lack of nephritis has been correlated with a normal level of complement. When 128 African-American cases with a normal C3 complement level were selected and compared with 770 controls, again, similar associations were found in the same SNPs (Table 3 ). C1q titers were not available in our cases. When we only considered C4 or CH50, the association results were less significant or only suggestive (data not shown).
Haplotype analyses
In haplotype analyses, the three significantly associated SNPs mentioned above (rs665691, rs172378 and rs12033074) resided in one haplotype block, which spans 6 kb in African Americans (Figure 1a ) (GAAG). In Hispanics, this haplotype block spans 9 kb and also contains additional SNPs (GAAGGG) (Figure 1b) . Two SNPs, rs665691 and rs172378, were highly correlated both in African Americans (D 0 ¼ 0.97, r 2 ¼ 0.7) and in Hispanics (D 0 ¼ 0.99, r 2 ¼ 0.88). In patients with no history of nephritis, the GAAG haplotype was significantly increased in the African-American cases compared with that in controls (28 cases vs 20% controls, P ¼ 0.0009, OR ¼ 1.52, 95% CI ¼ 1.19-1.93) and in the Hispanic cases compared with that in controls (55 cases vs 38% controls, P ¼ 0.002, OR ¼ 1.93, 95% CI ¼ 1.25-3.00). In addition to this haplotype, other haplotypic blocks were also suggestively significant. Indeed, an expanded haplotype in African Americans consists of the first nine SNPs in Table 2 (blocks 1, 2 and 3), (GAAGGGGAG) produces a P ¼ 5.56 Â 10
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with a frequency of 17% in cases and 9% in controls (OR ¼ 2.12, 95% CI ¼ 1.46-3.07). Conditional analyses in this haplotype suggest that either rs665691 or rs172378 is able to explain the entire observed global association.
Case-only analyses
Case-only analyses further showed that there is indeed a significant allelic distribution in SLE patients when kidney nephritis or C3 complement levels were considered as phenotypes. We first divided the AfricanAmerican SLE patients into two groups on the basis of the minimum reported C3 titer, that is, those with low C3 and those who never had lower than a normal range of C1Q and SLE in minority populations B Namjou et al C3 in their records. We consider patients with low C3 as cases and those with normal C3 as controls (141 cases and 128 controls). Indeed, the three alleles, G, A and G, for the SNPs, rs665691, rs172378 and rs12033074, respectively, were protective against the low level of C3 complement and alleles C, G and C were risk (best OR ¼ 2.13, 95% CI ¼ 1.37-3.38) (Table 4a ). In addition, when normalized C3 titers were considered as a , OR¼ 0.50 (0.37-0.68) (Table 4b ). For Hispanics, the number of cases for these variables was limited; however, the data were supportive (data not shown).
Discussion
In our large genotyping data for SLE patients and controls, none of the selected SNPs in the C1q gene were associated when evaluating the presence or absence of SLE as the phenotype. However, in subset analyses, we detected few associations, especially in our AfricanAmerican population and the results were supportive in our Hispanic population. These subphenotype associations should be interpreted with caution given the smaller sample sizes. On the other hand, as SLE is an extremely heterogeneous disease, with multiple correlated subphenotypes, stratifying by clinical findings can improve genetic homogeneity and thereby, more easily show genetic effects through improved statistical power.
Apart from multiple case reports of lupus with hereditary C1q deficiency, there are very limited studies that evaluate the polymorphisms of genes encoding for C1q (A, B, C) in lupus. In one recent study, similar to our study, a lack of association with SLE has been reported in Malaysian samples. 15 In another study, Martens et al. 16 reported the suggestive association of multiple SNPs, especially in the C1QB gene, with low C3, CH50 and more severe SLE in Caucasian trio families; however, none of their results were significant in case-control analyses and their sample sizes also were small. Abbreviations: BP, base pairs; CHISQ, chi-square; CHR, chromosome; FDR-q, false discovery rate-q; OR, odds ratio; SNP, single nucleotide polymorphism.
a P-value after 10000 permutations.
C1Q and SLE in minority populations B Namjou et al
They also have not genotyped the SNP, rs172378, in the C1QA gene. As mentioned above, in addition to various coding mutations in patients with complete deficiency of C1q, which are very rare, a common silent SNP (rs172378) of the C1QA gene has been found to be associated with SCLE. 11 There is no report of an association of this SNP with SLE. The major findings in SCLE patients were mostly limited to skin involvement, photosensitivity and no evidence of systemic involvement, such as renal disease. Interestingly, in our lupus cases with photosensitivity or those without ACR criterion renal disorder, we have detected similar allelic association to this SNP and the neighborhood SNPs that were in linkage C1Q and SLE in minority populations B Namjou et al disequilibrium. Petry et al. 17 has reported that almost in all cases with rare coding mutations, this silent SNP mutation can also be observed. On the basis of the minor allele frequency of this SNP (20-40%), this mutation is much more frequent in the general population than rare coding variants, and we expect that many only posses this single mutation and as reported, 11 it has been associated with lower than normal C1q levels and SCLE. In addition, both in our data and in reference National Center for Biotechnology Information (NCBI), there are significant differences in allele frequency for this SNP and for the SNP rs665691 between African-American and Caucasian normal controls. Indeed the minor allele A in African Americans for the SNP rs172378 was the major allele in Europeans. In Hispanics, it was somewhere in the middle (41%). Similarly, in the SNP rs665691, the major allele G in Europeans was the minor allele in African Americans. This SNP is located on the promoter of the C1QA gene and in linkage disequilibrium (D 0 ¼ 1) and is o2 kb from the SNP rs587585 that Martens et al. 16 reported to be suggestively associated with low CH50 and C1q in Caucasians. Both of these SNPs are located in the promoter/regulatory region of the C1QA gene. In animal studies, a polymorphism in this regulatory region has also been associated with low C1q levels and the development of nephritis in New Zealand Black mice and therefore, the region upstream of C1qA could be potentially important. 18 It is unclear whether these polymorphisms may play some triggering role in initiating antibodies against C1q which are thought to play a pathogenic role in lupus nephritis. 19 For the SNP rs172378, the allele A (major allele in Caucasians and minor in African Americans) is also reported to be related to lower than normal levels of C1q in Caucasian SCLE patients. 11 Although we do not have C1q titers in our samples, we did detect the significant difference in levels of C3 in African Americans but in the opposite direction. The mean normalized titer of C3 in African Americans for AA homozygotes was 0.33 (s.d. ¼ 1.06) in comparison with GG homozygotes that was À0.17 (s.d. ¼ 0.94), and the P-value obtained by t-test was P ¼ 0.007. For heterozygotes, a value of P ¼ 0.01 was observed (mean ¼ À0.09, s.d. ¼ 1.06). This observed effect with C3 complement could very likely be secondary to kidney nephritis, in which we detected a similar difference in a case-only analysis. In other clinical reports, it has been reported that the G allele of this SNP (rs172378) is associated with shorter remissions to rituximab therapy in patients with folicular lymphoma and is also associated with systemic metastasis in patients with breast cancer. 20, 21 This might be consistent biologically with our results in case-only analyses, in which the G allele of this SNP (rs172378) was associated with more severe disease and kidney nephritis in African Americans and Hispanics. Furthermore, the co-occurrence of the European major allele A with rare coding mutations in C1q 17 could be because of linkage disequilibrium and other unknown factors. Overall, our data, as well as those of others suggest that both the alleles (A and G) of the SNP rs172378 play important roles in different aspects of immune-mediated diseases, such as SLE.
In summary, although we were unable to find an association between SNPs evaluated in the C1q gene and SLE, there was evidence of an association in particular subsets of lupus patients. Further studies with higher SNP densities in this region and other complement components are necessary to elucidate the complex genetics and phenotypic interactions.
Materials and methods
Recruitment and biological sample collection
This study included 2214 participants (1235 SLE cases and 979 controls) enrolled in the Lupus Family Registry and Repository and the Lupus Genetics Studies at the Oklahoma Medical Research Foundation as described earlier 22 and from additional collaborators. 23, 24 The demographics, numbers of samples and frequency of the 11 ACR criteria are provided in Tables 5a and 5b. All the protocols were approved by the Institutional Review Boards at each respective institution. All the patients met 4 of the 11 revised 1997 ACR criteria for the classification of SLE. 25 Ethnicity was self-reported and verified by principal component (PC) analysis. Blood samples were collected from each participant, and genomic DNA was isolated and stored using standard methods. The complement C3 or C4 titers that have been used were were used. GenTrain scores measure the reliability of SNP detection on the basis of the distribution of genotypic classes. To minimize sample misidentification, data from 91 SNPs that had been genotyped earlier on 42.12% of the samples were used to verify sample identity. In addition, at least one sample genotyped earlier was randomly placed on each Illumina Infinium BeadChip (Illumina) and used to track samples throughout the genotyping process.
Statistical analyses
Testing for association was completed using PLINK (Purcell S., Center for Human Genetic Research (CHGR), Massachusetts General Hospital, Boston, MA, USA).
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For each SNP, missing data proportions for cases and controls, minor allele frequency and exact tests for departures from Hardy-Weinberg expectations were calculated. Haploview (Barrett JC, The Broad Institute of MIT and Harvard, MA, USA) version 4.0 27 was used to estimate the linkage disequilibrium between markers and haplotype structures in the different racial groups and haplotype analysis. Conditional haplotype analyses were conducted using WHAP program version 2.09 (Purcell S., Massachusetts General Hospital, Boston, MA, USA). To correct for multiple testing, FDR methods were used and Q-values were calculated using PLINK. 26 Qvalues correspond to the proportion of false positives among the results. Thus, Q-values o0.05 signify o5% of false positives and are taken as a measure of significance. In the case-only analyses, permutation P-values are also reported after 10 000 random permutations using the Haploview program. 27 To estimate the power of study for the subgroups, we used the genetic power calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/). We assumed that the high-risk allele frequency is equal to that of the marker allele and both were defined to be 0.5. At this allele frequency, the additive, dominant and recessive modes of inheritance have equal power and it is therefore, a conservative estimate. We assumed a disease prevalence of 1 in 10 000, an OR for heterozygotes of 1.5 and an OR for individuals homozygous for the risk allele of 2.0. We also assumed a D 0 of 0.9 (Br 2 ¼ 0.8). Finally, we assumed a type I error rate of 0.05 (reasonable, given the results from earlier studies and the biologically motivated hypotheses) and that we would conduct a 1 degree of freedom test for allelic association.
Stratification analyses
To account for potential confounding because of population, substructure or admixture in these samples, PC analyses were performed 28 using all SNPs (numbering 20 506 genotyped on these subjects as part of a large effort to determine the genetic susceptibility in SLE); an exception were those SNPs within the HLA region and other known associations identified by genome scan. 29 The Eigen values and Eigen vectors were computed, and the scree plot and the Tracy-Widom statistic were used to determine the number of PCs to adjust for during the analysis. Four PCs were identified that explained a total of B60% of the observed genetic variation. The PC analyses scores were used to identify individuals who were genetically distant from other samples and prone to introducing admixture bias. A total of 137 AfricanAmerican samples and 92 Hispanic samples were consequently removed from the analysis. After removing these genetic outliers, duplicates and related individuals, genomic control analysis was performed to calculate the inflation factor l (lambda) using all SNPs minus HLA region and earlier identified genes (18 446 SNPs, 92% of original SNPs), which produced a l ¼ 1.03 in Hispanics and a l ¼ 1.08 in African Americans. The inflation factor is a measure that quantifies the degree to which population stratification increases the w 2 -test statistic. Only the Hispanic sample required PC analyses as covariates in the logistic regression model to remove the final source of confounding through admixture to obtain the above inflation factor.
